Memory and Aging Center, University of California at San Francisco, 675 Nelson Rising Lane, Suite 190, San Francisco, CA, USA.
Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, USA.
Alzheimers Res Ther. 2019 Jan 31;11(1):13. doi: 10.1186/s13195-019-0470-7.
The tau positron emission tomography (PET) ligand F-flortaucipir binds to paired helical filaments of tau in aging and Alzheimer's disease (AD), but its utility in detecting tau aggregates in frontotemporal dementia (FTD) is uncertain.
We performed F-flortaucipir imaging in patients with the FTD syndromes (n = 45): nonfluent variant primary progressive aphasia (nfvPPA) (n = 11), corticobasal syndrome (CBS) (n = 10), behavioral variant frontotemporal dementia (bvFTD) (n = 10), semantic variant primary progressive aphasia (svPPA) (n = 2) and FTD associated pathogenic genetic mutations microtubule-associated protein tau (MAPT) (n = 6), chromosome 9 open reading frame 72 (C9ORF72) (n = 5), and progranulin (GRN) (n = 1). All patients underwent MRI and β-amyloid biomarker testing via C-PiB or cerebrospinal fluid. F-flortaucipir uptake in patients was compared to 53 β-amyloid negative normal controls using voxelwise and pre-specified region of interest approaches.
On qualitative assessment, patients with nfvPPA showed elevated F-flortacupir binding in the left greater than right inferior frontal gyrus. Patients with CBS showed elevated binding in frontal white matter, with higher cortical gray matter uptake in a subset of β-amyloid-positive patients. Five of ten patients with sporadic bvFTD demonstrated increased frontotemporal binding. MAPT mutation carriers had elevated F-flortaucipir retention primarily, but not exclusively, in mutations with Alzheimer's-like neurofibrillary tangles. However, tracer retention was also seen in patients with svPPA, and the mutations C9ORF72, GRN predicted to have TDP-43 pathology. Quantitative region-of-interest differences between patients and controls were seen only in inferior frontal gyrus in nfvPPA and left insula and bilateral temporal poles in MAPT carriers. No significant regional differences were found in CBS or sporadic bvFTD. Two patients underwent postmortem neuropathological examination. A patient with C9ORF72, TDP-43-type B pathology, and incidental co-pathology of scattered neurofibrillary tangles in the middle frontal, inferior temporal gyrus showed corresponding mild F-flortaucipir retention without additional uptake matching the widespread TDP-43 type B pathology. A patient with sporadic bvFTD demonstrated punctate inferior temporal and hippocampus tracer retention, corresponding to the area of severe argyrophilic grain disease pathology.
F-flortaucipir in patients with FTD and predicted tauopathy or TDP-43 pathology demonstrated limited sensitivity and specificity. Further postmortem pathological confirmation and development of FTD tau-specific ligands are needed.
tau 正电子发射断层扫描(PET)配体 F-flortaucipir 与衰老和阿尔茨海默病(AD)中的 tau 双螺旋丝结合,但在额颞叶痴呆(FTD)中检测 tau 聚集物的效用尚不确定。
我们对患有 FTD 综合征的患者进行了 F-flortaucipir 成像(n=45):非流利性变异原发性进行性失语症(nfvPPA)(n=11)、皮质基底节综合征(CBS)(n=10)、行为变异额颞叶痴呆(bvFTD)(n=10)、语义变异原发性进行性失语症(svPPA)(n=2)和 FTD 相关致病性基因突变微管相关蛋白 tau(MAPT)(n=6)、染色体 9 开放阅读框 72(C9ORF72)(n=5)和颗粒蛋白前体(GRN)(n=1)。所有患者均接受 MRI 和β-淀粉样蛋白生物标志物检测,方法为 C-PiB 或脑脊液。使用体素和预指定的感兴趣区域方法,将患者的 F-flortaucipir 摄取与 53 名β-淀粉样蛋白阴性的正常对照进行比较。
在定性评估中,nfvPPA 患者的左侧下额回比右侧下额回显示出更高的 F-flortacupir 结合。CBS 患者表现为额叶白质结合增加,在一部分β-淀粉样蛋白阳性患者中,皮质灰质摄取更高。10 名散发性 bvFTD 患者中有 5 名表现出额颞部结合增加。MAPT 突变携带者主要表现为 F-flortaucipir 保留,但并非排他性地表现为具有阿尔茨海默样神经原纤维缠结的突变。然而,在 svPPA 患者以及突变 C9ORF72、GRN 预测存在 TDP-43 病理学的患者中也观察到示踪剂保留。仅在 nfvPPA 中,在左侧岛叶和双侧颞极,在 MAPT 携带者中,在额下回发现了患者与对照组之间的定量区域感兴趣差异。在 CBS 或散发性 bvFTD 中未发现显著的区域差异。两名患者接受了死后神经病理学检查。一名携带 C9ORF72、TDP-43 型 B 病理学和偶发神经原纤维缠结的中间额、下颞叶散在共病的患者,表现出与广泛的 TDP-43 型 B 病理学相匹配的轻度 F-flortaucipir 保留,而没有额外的摄取。一名患有散发性 bvFTD 的患者表现出点状下颞叶和海马体示踪剂保留,与严重的银染颗粒病病理学区域相对应。
在患有 FTD 和预测 tau 病或 TDP-43 病理学的患者中,F-flortaucipir 的敏感性和特异性有限。需要进一步的死后病理证实和开发 FTD tau 特异性配体。